How to access Alecensa for ALK-positive non-small-cell lung cancer from Qatar: 2026 pathway via NCCCR Hamad Medical Corporation
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Qatar's adult medical oncology service runs out of the National Center for Cancer Care and Research (NCCCR) at Hamad Medical Corporation in Doha. NCCCR is the country's reference centre for adult cancer care, with a comprehensive medical oncology team, dedicated thoracic oncology service, in-house molecular pathology capability, and a weekly thoracic and molecular tumour board. For a Qatari adult with newly diagnosed ALK-positive metastatic non-small cell lung cancer (NSCLC), or with completely resected ALK-positive stage IB to IIIA disease, Alecensa (alectinib) is the standard-of-care first-line ALK tyrosine kinase inhibitor and is dispensed through NCCCR's institutional oncology pharmacy. Sidra Medicine is the paediatric reference centre and is not the relevant centre for this adult oncology pathway.
This page explains how the pathway works in 2026 for a Qatar-resident adult: who qualifies, where the molecular diagnostic confirmation happens, how the prescription is written and filled at NCCCR or through Qatari private-sector oncology, how the written quote works, what to monitor on therapy, and how the multi-year treatment course settles into a Qatari family's life.
Ask about Alecensa in Qatar
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Why Alecensa, and why now
Alecensa is alectinib, a second-generation, central-nervous-system-penetrant ALK tyrosine kinase inhibitor developed by Roche with Chugai Pharmaceutical. The FDA approved Alecensa for first-line ALK-positive metastatic NSCLC in 2017 based on the ALEX trial, where median progression-free survival was 34.8 months on Alecensa versus 10.9 months on crizotinib and CNS objective response rate was 81 percent versus 50 percent. The April 2024 label expansion added adjuvant treatment for stage IB to IIIA ALK-positive NSCLC after complete resection, based on the ALINA trial (disease-free survival hazard ratio 0.24 favouring Alecensa).
Alecensa is registered with the Qatar Ministry of Public Health and is part of NCCCR's standard first-line approach for confirmed ALK-positive NSCLC. The eligibility gatekeeper is biomarker confirmation: documented ALK rearrangement by IHC, FISH, or NGS.
What Alecensa is, in plain language
Alecensa is an oral capsule. Four 150 mg capsules per dose, twice daily, twelve hours apart, with food. Total daily dose 1,200 mg. Room temperature storage; no refrigeration. There is no infusion, no inpatient stay, no certified-centre requirement. After NCCCR or a private-sector oncologist writes the first prescription, the dispensing pharmacy fills a 30-day or 60-day supply and the patient takes Alecensa at home.
For metastatic disease, treatment is until progression or intolerable toxicity; median time on therapy in ALEX was 28.1 months. For the adjuvant indication, treatment is fixed at 2 years per the ALINA protocol.
The mechanism: ALK rearrangement produces a constitutively active fusion protein (most commonly EML4-ALK) that drives malignant transformation. Alecensa binds the ATP-binding pocket of the ALK kinase domain approximately 10-fold more potently than crizotinib, achieves meaningful CNS exposure, and covers most resistance mutations except G1202R.
The biomarker requirement
Alecensa is a targeted therapy. ALK testing at NCCCR is performed in-house using IHC (Ventana D5F3) as the primary screen, with FISH or NGS confirmation when histology is borderline or when fusion-partner detail will matter at later lines. For complex NGS panels or liquid biopsy, samples may be sent to international reference labs (Caris Life Sciences, Foundation Medicine).
If the original diagnostic biopsy did not include ALK testing, archived tissue submission or re-biopsy is standard.
Eligibility at the NCCCR oncology clinic
For Qatar-resident patients, the medical and thoracic oncology service applies the FDA, EMA, and major-guideline criteria:
1. Histologically confirmed NSCLC. 2. Confirmed ALK rearrangement by IHC, FISH, or NGS. 3. For metastatic indication: stage IV disease confirmed by contrast CT, PET-CT, and brain MRI. 4. For adjuvant indication: stage IB (tumour 4 cm or larger) through IIIA disease, complete resection, and confirmed ALK rearrangement on resected tissue. 5. Baseline laboratory workup: CBC, comprehensive metabolic panel including LFTs, creatine kinase, bilirubin. 6. Baseline ECG with QTc and heart rate. 7. Baseline pulmonary assessment. 8. Pregnancy and lactation screen; contraception documented for women of reproductive potential. 9. Drug interaction screen including herbal products and grapefruit.
A Qatar-resident patient should arrive at the NCCCR thoracic oncology referral with the most recent pathology, imaging, and prior treatment history. Reserve Meds organises the documentation pack.
Qatar prescribing and dispense picture, plainly
In 2026 the Qatar oncology pathway for Alecensa is centred on:
- NCCCR (National Center for Cancer Care and Research) at Hamad Medical Corporation: the adult cancer reference centre. Medical oncology and thoracic oncology services. In-house molecular pathology. Weekly molecular tumour board. Institutional pharmacy dispenses Alecensa on the NCCCR oncology formulary. - Private-sector oncology: Al Ahli Hospital, Aspetar (sports medicine focused, not the typical oncology route), and the Sidra adult adjacency are limited; the dominant operational pathway is NCCCR public-sector. - For Qatar nationals, the NCCCR pathway includes coverage under the national health insurance scheme administered by the National Health Insurance Company (Seha) for approved oncology medications.
The pathway:
1. Diagnosis and molecular confirmation: at NCCCR pathology, with reference-lab support for complex molecular work. 2. Multidisciplinary tumour board review: weekly NCCCR thoracic / molecular tumour board documents the rationale and treatment plan. 3. Treatment approval: through NCCCR's chemotherapy and high-cost drug committee for institutional dispensing. 4. Pharmacy dispense: NCCCR institutional pharmacy. Refill is monthly with ongoing monitoring lab documentation.
Cost and quote
Medicine price: quote on request. You get a written quote for your case before you commit.
For Qatari nationals on the NCCCR institutional pathway with national health insurance coverage, out-of-pocket cost for Alecensa is typically minimal. For expatriate residents and self-pay families, the pharmacy issues a separated quote: drug cost, monitoring labs, imaging, oncologist visits, and any Reserve Meds coordination fee disclosed in writing.
Monitoring on therapy
- Liver function tests: every 2 weeks for the first 3 months, then monthly. - Creatine kinase: every 2 weeks for the first month, then every 4 weeks. - Heart rate and ECG: as clinically indicated. - Pulmonary symptoms: any new or worsening dyspnoea, cough, or fever triggers HRCT and pulmonology input for ILD workup. - Photosensitivity counselling: sun avoidance and high-SPF sunscreen, salient in Qatar's UV-intense climate. - Disease assessment: contrast CT or PET-CT every 8 to 12 weeks; brain MRI every 12 weeks if CNS metastases at baseline.
Religious, ethical, and family-logistics framing
Alecensa is an oral small molecule with no animal-source material in standard manufacturing, no donor cells. Families who have religious questions about a medicine can discuss them with their own scholar or physician.
The family-logistics burden sits in chronicity and adherence. Twice-daily dosing with food for 2 to 3 years (metastatic) or 2 years (adjuvant), with monitoring labs every 2 weeks initially, requires a sustained routine. Reserve Meds documents the practical scaffolding (medication diary, smartphone reminders, family co-monitoring) at first refill.
When Alecensa is not the right call
Alecensa is not appropriate for ALK-negative disease, patients with a history of clinically significant interstitial lung disease, severe hepatic impairment (Child-Pugh C), or pregnancy. For confirmed ALK-positive disease where Alecensa is not the chosen first-line, lorlatinib (third-generation, increasing first-line use based on CROWN trial) and brigatinib (second-generation alternative) are the standard alternatives. Crizotinib is rarely first-line in 2026. The clinical conversation with the treating oncologist about which TKI to start is the central decision.
What Reserve Meds does on this case
We are a US-based digital health company. We are not the prescriber and not the dispensing pharmacy. On a Qatar Alecensa case we build the document pack, support the NCCCR referral conversation, coordinate the insurance and institutional approval pathway, set up the first dispense at NCCCR or the chosen private-sector pharmacy, and stay with the case through the refill cycle. Clinical decisions remain with your treating medical oncologist and the NCCCR multidisciplinary tumour board.
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating medical oncologist and the multidisciplinary tumour board.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Frequently asked questions
How can I get Alecensa in Qatar if it is not approved or available there?
Reserve Meds coordinates US-sourced Alecensa for patients in Qatar through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Qatar and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Alecensa in Qatar through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Alecensa. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Qatar, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Alecensa in Qatar through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Alecensa to a patient in Qatar?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Alecensa to your treating physician or hospital pharmacy in Qatar, with appropriate handling for the product.
How long does it take, and what does Alecensa in Qatar cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Alecensa in Qatar?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.